← All indications
Dwarfism, Pituitary
A form of dwarfism caused by complete or partial GROWTH HORMONE deficiency, resulting from either the lack of GROWTH HORMONE-RELEASING FACTOR from the HYPOTHALAMUS or from the mutations in the growth hormone gene (GH1) in the PITUITARY GLAND. It is also known as Type I pituitary dwarfism. Human hypophysial dwarf is caused by a deficiency of HUMAN GROWTH HORMONE during development.
Drugs by status
Approved for this indication (7)
Phase 3 trials (1)
Phase 1 trials (1)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (50)
- Roche
- Novo Nordisk
- Genentech
- Merck KGaA
- Pfizer
- GeneScience Pharmaceuticals Co., Ltd.
- Huazhong University of Science and Technology
- Central South University
- Hebei University
- Anhui Medical University
- First People's Hospital of Hangzhou
- Guangxi Medical University
- Guangzhou Medical University
- Hacettepe University
- Harbin Medical University
- Kunming Medical University
- Nanjing Medical University
- Shaoxing Second Hospital
- University of Southern California
- Xuzhou Medical University
- Capital Medical University
- Fudan University
- Peking University
- Wenzhou Medical University
- Dalian Medical University
- Soochow University
- Xiamen University
- Zhejiang Chinese Medical University
- Zhengzhou University
- Zhejiang University
- +20 more
Organization Involved with Phase 3 Indications (17)
- Eli Lilly
- BioPartners GmbH
- Cinnagen
- LG
- Teva
- Versartis Inc.
- Xiamen Amoytop Biotech Co., Ltd.
- Daewoong Pharmaceutical Co. LTD.
- Baylor University
- Keio University
- Jilin University
- University of Naples Frederico II
- Ascendis Pharma, Inc.
- Opko
- National Center for Child Health and Development, Japan
- Ferring
- Visen Pharmaceuticals
Organization Involved with Phase 2 Indications (16)
- Ambrx
- Altus Pharmaceuticals
- Genexine, Inc.
- National Institutes of Health (NIH)
- Aarhus University
- China Three Gorges University, Yichang, China
- Sichuan University
- Yonsei University
- Chongqing Medical University
- Tsinghua University
- Hanmi Pharmaceutical
- University of Lyon
- Premier Research Group
- Accelsiors
- Center for Neurological Studies (CNS)
- Lumos Pharma
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (9)